CN103108634B - 用于治疗肝病、肺病、糖尿病并发症和心血管疾病的二苯醚化合物 - Google Patents

用于治疗肝病、肺病、糖尿病并发症和心血管疾病的二苯醚化合物 Download PDF

Info

Publication number
CN103108634B
CN103108634B CN201180037004.1A CN201180037004A CN103108634B CN 103108634 B CN103108634 B CN 103108634B CN 201180037004 A CN201180037004 A CN 201180037004A CN 103108634 B CN103108634 B CN 103108634B
Authority
CN
China
Prior art keywords
compound
formula
nafld
nash
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180037004.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103108634A (zh
Inventor
S·纳拉亚南
J·穆坎
J·库拉辛格尔
G·辛格
G·巴拉苏布拉玛尼安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orchid Pharma Ltd
Original Assignee
Orchid Chemicals and Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orchid Chemicals and Pharmaceuticals Ltd filed Critical Orchid Chemicals and Pharmaceuticals Ltd
Publication of CN103108634A publication Critical patent/CN103108634A/zh
Application granted granted Critical
Publication of CN103108634B publication Critical patent/CN103108634B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201180037004.1A 2010-07-28 2011-03-28 用于治疗肝病、肺病、糖尿病并发症和心血管疾病的二苯醚化合物 Expired - Fee Related CN103108634B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN2140CH2010 2010-07-28
IN2140/CHE/2010 2010-07-28
IN525/CHE/2011 2011-02-23
IN525CH2011 2011-02-23
PCT/IN2011/000210 WO2012014218A1 (en) 2010-07-28 2011-03-28 Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases

Publications (2)

Publication Number Publication Date
CN103108634A CN103108634A (zh) 2013-05-15
CN103108634B true CN103108634B (zh) 2015-08-12

Family

ID=44247871

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180037004.1A Expired - Fee Related CN103108634B (zh) 2010-07-28 2011-03-28 用于治疗肝病、肺病、糖尿病并发症和心血管疾病的二苯醚化合物

Country Status (11)

Country Link
US (1) US20140187594A1 (enExample)
EP (2) EP2987488A1 (enExample)
JP (1) JP5957452B2 (enExample)
CN (1) CN103108634B (enExample)
AU (1) AU2011284256B8 (enExample)
CA (1) CA2805245A1 (enExample)
ES (1) ES2565487T3 (enExample)
HU (1) HUE028725T2 (enExample)
PL (1) PL2598142T3 (enExample)
WO (1) WO2012014218A1 (enExample)
ZA (1) ZA201300822B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3362053A4 (en) * 2015-10-16 2019-04-17 Hadasit Medical Research Services and Development Ltd. TREATMENT OF NON-ALCOHOLIC FATTYLENE OR NON-ALCOHOLIC STEATOHEPATITIS WITH 6-MERCAPTOPURIN WITH DELAYED RELEASE
TWI762634B (zh) 2017-05-05 2022-05-01 大陸商上海赫普化醫藥技術有限公司 胺基-芳基-苯甲醯胺化合物及其使用方法
CN113750089B (zh) * 2021-10-13 2023-09-19 南方医科大学南方医院 2-芳基-1,3二氢苯并咪唑衍生物在制备治疗慢性肝病的药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288341A1 (en) * 2003-01-17 2005-12-29 Bexel Pharmaceuticals, Inc. Novel diphenyl ether derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08109175A (ja) * 1994-10-07 1996-04-30 Torii Yakuhin Kk チアゾリジン−２−オンエステル誘導体
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US6794401B2 (en) 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
JP2008533122A (ja) * 2005-03-18 2008-08-21 オーキッド ケミカルズ アンド ファーマシューティカルズ リミテッド 新規なチロシン誘導体
WO2006138475A2 (en) * 2005-06-16 2006-12-28 Jenrin Discovery Mao-b inhibitors useful for treating obesity
WO2008106166A2 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors
JP2010520306A (ja) * 2007-03-07 2010-06-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ エストロゲン関連受容体−αモジュレーターとしての置換フェノキシチアゾリジンジオン
WO2009030968A1 (en) * 2007-09-05 2009-03-12 Orchid Research Laboratories Limited Mao a inhibitors with a diphenyl ether-substructure.
WO2009070781A1 (en) * 2007-11-30 2009-06-04 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288341A1 (en) * 2003-01-17 2005-12-29 Bexel Pharmaceuticals, Inc. Novel diphenyl ether derivatives

Also Published As

Publication number Publication date
JP2013532682A (ja) 2013-08-19
AU2011284256B2 (en) 2014-05-29
CN103108634A (zh) 2013-05-15
ZA201300822B (en) 2014-04-30
ES2565487T3 (es) 2016-04-05
US20140187594A1 (en) 2014-07-03
AU2011284256A1 (en) 2013-02-14
AU2011284256B8 (en) 2014-11-13
WO2012014218A1 (en) 2012-02-02
CA2805245A1 (en) 2012-02-02
EP2987488A1 (en) 2016-02-24
HUE028725T2 (en) 2016-12-28
AU2011284256A8 (en) 2014-11-13
JP5957452B2 (ja) 2016-07-27
EP2598142B1 (en) 2015-12-16
EP2598142A1 (en) 2013-06-05
PL2598142T3 (pl) 2016-06-30

Similar Documents

Publication Publication Date Title
JP2010505783A (ja) 非アルコール性脂肪肝炎の治療
US20230130766A1 (en) Mono and combination therapies with ulk1/2 inhibitors
CN121335698A (zh) 用于治疗肝脏病症或心脏代谢疾病的包含THR-β激动剂和GLP-1R激动剂的组合
TWI394748B (zh) 新穎的雜環二苯基醚類化合物
US12310967B2 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
KR102191405B1 (ko) 간 질환 예방 또는 치료용 조성물
WO2012112558A1 (en) Compositions and methods for the treatment of obesity and related disorders
JP2024510249A (ja) 神経疾患を治療するための組成物およびその方法
AU2011284256B8 (en) Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases
CN112105598B (zh) 用于预防或治疗肥胖或代谢综合征的化合物和包含其的药学组合物
CN111356764A (zh) 降低血清胆固醇和pcsk9的组合物和方法
US12274703B2 (en) Compositions and methods of treatment for neurological disorders comprising a dementia
CA3135943A1 (en) Novel compound and method for preventing or treating of respiratory disease comprising the same as an active ingredient
JP2008530242A (ja) 血漿中のグルコースレベル、コレステロールレベル及びトリグリセリドレベルを低下させるための５−［４−（４−（２−アミノ−２−メトキシカルボニルエチル）フェノキシ）ベンジリデン］チアゾリジン−２，４−ジオン誘導体及び関連化合物
KR101686872B1 (ko) Tlr4에 lps와의 경쟁적 결합을 통한 항산화 및 항염증 활성을 갖는 신규 화합물 및 이의 의학적 용도
US20230104617A1 (en) Compound for treating alzheimers disease
EP2412705A1 (en) Novel therapeutic agent for cognitive impairment
CN110483367A (zh) 吲哚类化合物在制备药物中的用途
CN113262218B (zh) 异硫氰酸酯类化合物的用途
KR20250023492A (ko) 플라보노이드 화합물, 및 섬유성 병태를 치료하기 위한 플라보노이드 화합물의 사용 방법 및 물질
KR20260060996A (ko) 크로몬 유도체의 TGF-beta 신호전달 억제 및 자가포식 촉진 활성을 이용한 섬유증 예방 또는 치료용 약학적 조성물로의 용도
RU2588133C2 (ru) Ниациновые миметики и способ их использования
KR20260060993A (ko) 크로몬 유도체의 TGF-beta 신호전달 억제 및 자가포식 촉진 활성을 이용한 섬유증 예방 또는 치료용 약학적 조성물로의 용도
CN116568291A (zh) 取代的芳香族化合物及其药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150812

Termination date: 20200328

CF01 Termination of patent right due to non-payment of annual fee